Tasly withdraws traditional Chinese medicine registration application

Tasly Pharmaceutical Group announced the withdrawal of its drug registration application for lung heat treatment granules after initially submitting it to regulators in January 2024.

The company's cumulative research and development investment for this project reached RMB 11.37 million. Tasly stated the withdrawal would not significantly impact its current or future production and operational performance.